Genkyotex

Recent Finacing

Series D

Recent Raise

$19.7M

Genkyotex develops selective NOX1/4 small-molecule inhibitors, advancing GKT137831 in clinical trials for diabetic nephropathy and developing NOX-targeted therapies for fibrotic and inflammatory diseases.